Relieves muscle spasm associated with acute, painful musculoskeletal conditions. ANDA 213324, held by Unichem Laboratories. Cyclobenzaprine Hydrochloride.
As of Nov 21, 2026, ANDA 213324 (Cyclobenzaprine Hydrochloride), held by Unichem Laboratories, was first approved by FDA on Jul 6, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 6, 2020 | Original application | Approved | None posted |
| Cyclobenzaprine Hydrochloride5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Cyclobenzaprine Hydrochloride7.5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters